Hyperphosphatemia Market

Hyperphosphatemia is a condition characterized by an increase in serum phosphate levels above

4.5 mg/100 mL. It is a symptomatic effect/condition of another major underlying cause. The normal range for phosphorus is 2.5-4.5 mg/dL. Normal values may vary from laboratory to laboratory.

Hyperphosphatemia Epidemiology Segmentation in the 7MM from 2018 to 2030

  • Total Prevalent Cases of Chronic Kidney Disease
  • Diagnosed Chronic Kidney Disease Prevalent Cases
  • Stage-specific Distribution of Chronic Kidney Disease
  • Prevalent Cases of End-Stage Renal Disease (ESRD)
  • Number of ESRD patients undergoing Dialysis
  • Hyperphosphatemia Prevalence

Hyperphosphatemia Epidemiology Insights Observed in 2020

  • Hyperphosphatemia occurs in both men and women.
  • The total diagnosed prevalent cases of Chronic Kidney Disease (CKD) in 7MM, China, and Taiwan were found to be 27,063,599 in the year 2020.
  • The patients with Stage 3–5 CKD in the United States were observed to be 2,317,671.
  • The prevalence of ESRD in the United States was found to be 797,101 in the year 2020.
  • The prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis were estimated to be 481,050 in the United States whereas Germany accounted for 55,631 cases and Spain had 23,847 cases.

Hyperphosphatemia Market Insights

The Hyperphosphatemia market size was found to be  USD 3,976 million in 7MM in the year 2020.

Hyperphosphatemia Market Drivers

  • Promising pipeline activity with the newer mechanism of actions
  • Upsurging research and development
  • Large target population

Hyperphosphatemia Market Barriers

  • Poor knowledge of phosphate levels in food and phosphate management
  • High economic burden
  • Gastrointestinal side effects
  • High market competition
  • Lack of epidemiology data

Hyperphosphatemia Emerging Therapies

The emerging drugs in the Hyperphosphatemia market are

  • Ibsrela (Tenapanor) 
  • PT20, and several others

Hyperphosphatemia Key Players

The key companies in the Hyperphosphatemia market are 

  • Ardelyx
  • Shield Therapeutics, and several others